ML20213C237: Difference between revisions

From kanterella
Jump to navigation Jump to search
(StriderTol Bot change)
(StriderTol Bot change)
 
Line 16: Line 16:


=Text=
=Text=
{{#Wiki_filter:UNITED STATES NUCLEAR REGULATORY COMMISSION WASHINGTON, D.C. 20555-0001 July 31, 2020 MEMORANDUM TO:         Eugene Dacus, Director Office of Congressional Affairs FROM:                   Meraj Rahimi, Acting Chief           /RA/
{{#Wiki_filter:UNITED STATES NUCLEAR REGULATORY COMMISSION WASHINGTON, D.C. 20555-0001 July 31, 2020 MEMORANDUM TO:
Regulatory Guidance and Generic Issues Branch Division of Engineering Office of Nuclear Regulatory Research
Eugene Dacus, Director Office of Congressional Affairs FROM:
Meraj Rahimi, Acting Chief  
/RA/
Regulatory Guidance and Generic Issues Branch Division of Engineering Office of Nuclear Regulatory Research  


==SUBJECT:==
==SUBJECT:==
TRANSMITTAL OF CONGRESSIONAL REVIEW ACT FORMS FOR REGULATORY GUIDE (RG) 1.187, REVISION 2, GUIDANCE FOR IMPLEMENTATION OF 10 CFR 50.59, CHANGES, TESTS, AND EXPERIMENTS Enclosed for your signature are three Congressional Review Act forms for Regulatory Guide (RG) 1.187, Revision 2, Guidance for Implementation of 10 CFR 50.59, Changes, Tests, and Experiments. Please arrange to have these forms submitted to the President of the Senate, the Speaker of the House of Representatives, and the U.S. Government Accountability Office.
TRANSMITTAL OF CONGRESSIONAL REVIEW ACT FORMS FOR REGULATORY GUIDE (RG) 1.187, REVISION 2, GUIDANCE FOR IMPLEMENTATION OF 10 CFR 50.59, CHANGES, TESTS, AND EXPERIMENTS Enclosed for your signature are three Congressional Review Act forms for Regulatory Guide (RG) 1.187, Revision 2, Guidance for Implementation of 10 CFR 50.59, Changes, Tests, and Experiments. Please arrange to have these forms submitted to the President of the Senate, the Speaker of the House of Representatives, and the U.S. Government Accountability Office.  


==Enclosures:==
==Enclosures:==
Line 26: Line 29:
: 2. Regulatory Guide 1.187, Revision 2 CONTACT: Robert Roche-Rivera, RES/DE/RGGIB 301-415-8113
: 2. Regulatory Guide 1.187, Revision 2 CONTACT: Robert Roche-Rivera, RES/DE/RGGIB 301-415-8113


Package: ML20125A685, Memo: ML20213C237 RG 1.187, Revision 2: ML20125A730, GAO forms: ML20213C069, ML20213C098, ML20213C104 OFFICE RES/DE/RGGIB       RES/DE/RGGIB NAME R. Roche-Rivera       R. Rahimi DATE 07/31/2020             7/31/2020}}
Package: ML20125A685, Memo: ML20213C237 RG 1.187, Revision 2: ML20125A730, GAO forms: ML20213C069, ML20213C098, ML20213C104 OFFICE RES/DE/RGGIB RES/DE/RGGIB NAME R. Roche-Rivera R. Rahimi DATE 07/31/2020 7/31/2020}}

Latest revision as of 03:36, 4 December 2024

Memo for Cra Forms - RG 1.187 (Rev 2) Guidance for Implementation of 10 CFR 50.59, Changes, Tests, and Experiments
ML20213C237
Person / Time
Issue date: 07/31/2020
From: Meraj Rahimi
NRC/RES/DE
To: Eugene Dacus
Office of Congressional Affairs
Roche-Rivera R
Shared Package
ML20125A685 List:
References
Download: ML20213C237 (2)


Text

UNITED STATES NUCLEAR REGULATORY COMMISSION WASHINGTON, D.C. 20555-0001 July 31, 2020 MEMORANDUM TO:

Eugene Dacus, Director Office of Congressional Affairs FROM:

Meraj Rahimi, Acting Chief

/RA/

Regulatory Guidance and Generic Issues Branch Division of Engineering Office of Nuclear Regulatory Research

SUBJECT:

TRANSMITTAL OF CONGRESSIONAL REVIEW ACT FORMS FOR REGULATORY GUIDE (RG) 1.187, REVISION 2, GUIDANCE FOR IMPLEMENTATION OF 10 CFR 50.59, CHANGES, TESTS, AND EXPERIMENTS Enclosed for your signature are three Congressional Review Act forms for Regulatory Guide (RG) 1.187, Revision 2, Guidance for Implementation of 10 CFR 50.59, Changes, Tests, and Experiments. Please arrange to have these forms submitted to the President of the Senate, the Speaker of the House of Representatives, and the U.S. Government Accountability Office.

Enclosures:

1. Congressional Review Act Forms
2. Regulatory Guide 1.187, Revision 2 CONTACT: Robert Roche-Rivera, RES/DE/RGGIB 301-415-8113

Package: ML20125A685, Memo: ML20213C237 RG 1.187, Revision 2: ML20125A730, GAO forms: ML20213C069, ML20213C098, ML20213C104 OFFICE RES/DE/RGGIB RES/DE/RGGIB NAME R. Roche-Rivera R. Rahimi DATE 07/31/2020 7/31/2020